Marc Cohn is sharing his Parkinson’s disease diagnosis publicly for the first time. The “Walking in Memphis” artist, 65, took to Instagram on Thursday, Jan. 30 to share a health update with his fans ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Movement is key in helping to control symptoms of Parkinson’s disease (PD). To help promote the benefits of cycling as it ...

Doctors and researchers say ping pong can help slow Parkinson's disease. The South County Recreation Center in Bixby hosts ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...